Published in Medical Letter on the CDC and FDA, January 2nd, 2005
This IND filing is for its phase I/II clinical trials, using T cells produced in its T-cell growth platform, to restore the damaged immune systems of patients. The phase I/II trials will specifically examine the safety and potential efficacy of this growth platform in reconstituting the immune system of patients with certain cancers of the blood system.
This filing follows on from the announcement made on November 18, 2004, on CyGenics' collaboration with Cell...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.